SFM
EGRX

Systematic Financial Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Systematic Financial Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,635
Closed -$318K – 466
2020
Q2 		$318K Sell
6,635
-3,285
-33% -$164K 0.02% 319
2020
Q1 		$456K Sell
9,920
-630
-6% -$31.6K 0.03% 188
2019
Q4 		$634K Buy
10,550
+1,025
+11% +$61.1K 0.02% 292
2019
Q3 		$539K Sell
9,525
-7,200
-43% -$405K 0.02% 353
2019
Q2 		$931K Buy
+16,725
New +$872K 0.04% 341
2018
Q3 		– Sell
-19,030
Closed -$1.44M – 684
2018
Q2 		$1.44M Sell
19,030
-4,925
-21% -$310K 0.04% 367
2018
Q1 		$1.26M Sell
23,955
-2,050
-8% -$119K 0.03% 499
2017
Q4 		$1.39M Sell
26,005
-175
-0.7% -$9.74K 0.03% 460
2017
Q3 		$1.56M Buy
+26,180
New +$1.58M 0.03% 391

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Systematic Financial Management's EGRX Position: Q3 2020 in Review

Systematic Financial Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2020, closing a stake of 6,635 shares — an estimated $318K sold.

Systematic Financial Management first reported a position in EGRX in Q3 2017 and held it in 9 quarters. The position peaked at $1.56M in Q3 2017. 171 funds tracked by Wall St. Rank hold EGRX as of Q3 2020.

  • Systematic Financial Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Systematic Financial Management sold 6,635 Eagle Pharmaceuticals, Inc. shares in Q3 2020, an estimated $318K.
  • Systematic Financial Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 9 quarters.
  • Systematic Financial Management's Eagle Pharmaceuticals, Inc. position peaked at $1.56M in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2020.

Based on Systematic Financial Management's 13F filing for Q3 2020, filed 12 Nov 2020.